Clinical OMICS

NOV-DEC 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1040438

Contents of this Issue

Navigation

Page 4 of 51

www.clinicalomics.com November/December 2018 Clinical OMICs 3 Publisher & CEO MARY ANN LIEBERT President MARIANNE RUSSELL Group Publisher SANDE GIACCONE Editor in Chief CHRIS ANDERSON EVP, Strategic Development KEVIN DAVIES Commercial Director BILL LEVINE Production Editor ROBERT M. REIS Senior Editor JULIANA LEMIEUX, PH.D. Senior News Editor ALEX PHILIPPIDIS Chief Copy Editor STEVEN HERNACKI Contributing Editors CHRISTINA BENNETT, CAMILLE MOJICA REY, PH.D. Art Director JAMES LAMBO Online Product Manager SEAN HELMES Associate Director of Brand Marketing JENNIFER GATTI Online Editorial Supervisor KATHERINE VUKSANAJ Design & Layout DIANNE PAULET, BYRON DUQUE Advertising Sales Manager KAYLA MCCUTCHAN US West & Asia Pacific (kmccutchan@clinicalOMICs.com / 510-619-6988) Advertising Sales Manager REBECCA SHUMBATA US East, UK, & Europe (rshumbata@clinicalOMICs.com/ 617-435-4786) List Sales SCOTT PERILLO (sperillo@ClinicalOMICs.com / 914-740-2178) Sales Administrator FALLON MURPHY Advertising Material WANDA SANCHEZ (wsanchez@liebertpub.com) Clinical OMICs Advisory Board DANIEL H. FARKAS, PH.D., HCLD Chief Clinical Laboratory Officer, Celmatix JEFFREY GIBBS, J.D. Director, Hyman, Phelps, and McNamara PETER HARRSCH, PH.D. Executive Clinical/Forensic Specialist, Waters Corp. ROGER KLEIN, M.D., J.D. Medical Director, Molecular Pathology, Cleveland Clinic JASON PARK, M.D., PH.D. Assistant Professor, Dept. of Pathology, University of Texas Southwestern Medical Center STEPHEN C. PEIPER, M.D. Professor & Chair, Dept. of Pathology, Anatomy & Cell Biology, Thomas Jefferson University AMIT RASTOGI Senior Vice President, Strategy, Growth, and Innovation, Inova DAVID SMITH, PH.D. Professor of Laboratory Medicine and Pathology, Mayo Clinic KIMBERLY STRONG, PH.D. Director, Program in Genomics and Ethics, Medical College of Wisconsin LARRY WORDEN Vice President and Senior Partner, Market Diagnostics International The views, opinions, findings, conclusions, and recommenda- tions set forth in any article in Clinical OMICs are solely those of the authors of those articles and do not necessarily reflect the views, policy, or position of Clinical OMICs, its Publisher, or its editorial staff and should not be attributed to any of them. All advertisements are subject to review by the Publisher. The acceptance of advertisements does not constitute an endorse- ment of the product or service advertised. Clinical OMICs (ISSN-2334-1351) is published online bimonthly by GEN Publishing, 140 Huguenot St., 3rd Floor, New Rochelle, NY 10801-5215. For subscription information go to: www.clinicalomics.com Copyright © 2018 by GEN Publishing, New Rochelle, NY A s primary care and hospital readmissions rates have come under the watch- ful eye of CMS and private payers looking to deploy value-based reim- bursement models, it only makes sense that medical specialties should prepare for the move away from fee-for-service payments. Cancer care is no exception. With this dynamic in mind, a new oncology business, OneOncology, launched at the tail end of summer flush with an initial $200 million investment from equity firm General Atlantic (see story page 16). Its mission is simply stated: to provide its member com- munity oncologists across the coun- try with economies of scale, access to capital, and a common technol- ogy backbone that prepares them for value-based payment models. The need for community cancer centers to find ways to band together is apparent, said Tracy Dahl, a co-founder and CEO of the company. The way Dahl sees it, community cancer centers—defined as physician-led and -owned practices that are independent from either a hospital system or academic med- ical center—are poised to take the lead in providing high-value care in the future. From a financial perspective, they are well on their way, delivering care that costs up to 60% less than similar care delivered in an acute care setting. Now, to further this strength, OneOncology will leverage the technology expertise of Flatiron Health to provide a common technology and data back- bone to all OneOncology member practices. The idea is to make it easy for all the community oncologists within the company's network to share best prac- tices, care pathways and other operational tidbits, including providing clinical decision support for precision care. So why focus on community cancer centers? To begin with, according to the Community Oncology Alliance, nearly 55% of all people in this country bat- tling cancer receive care in a community setting. Combine this with the dou- ble-edged sword of an aging population's increasing cancer incidence, as well as people who develop cancer surviving longer than they ever have because of more effective treatments (meaning they make more visits to their community oncologists than they did in the past), and it is easy to see why many of these practices might need a helping hand. That is where OneOncology believes it will make a difference—more efficient delivery of care allows practices the ability to provide care for more patients. Shared best practice improve care quality. Banded together, a collection of com- munity oncologists numbering 1,000 or more physicians can get better prices on everything from paper clips to oncology drugs. Top this off with providing individual community cancer centers with access to capital for expansion of services, the purchase of equipment, or to add loca- tions and, on paper anyway, it looks like the management team at OneOncology has a significant opportunity ahead. FROM THE EDITOR Chris Anderson Editor in Chief Community Cancer Centers Move into the Spotlight

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - NOV-DEC 2018